Aleglitazar cas 475479-34-6

Aleglitazar, also known as RG-1439 or RO-0728804, is a peroxisome proliferator-activated receptor agonist (hence a PPAR modulator ) with affinity to PPARα and PPARγ, Aleglitazar improves Insulin Sensitivity, Glucose Control and Lipids in People with Type 2 Diabetes.Aleglitazar(R1439; RO-0728804) is a new dual PPAR-α/γ agonist with IC50 of 2.8 nM/4.6 nM. IC50 Value: 2.8 nM(PPAR-α); 4.6 nM(PPAR-γ) Target: PPARα/γ Aleglitazar (R1439) is a dual peroxisome proliferator-activated receptor (PPAR) agonist, with affinity to PPARα and PPARγ. Aleglitazar is being developed for the treatment of type II diabetes; It is currently in phase III clinical trials. In preliminary clinical studies, Aleglitazar has been demonstrated to improve hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus. Aleglitazar has beneficial effects on both lipid and glucose parameters and may have a therapeutic role in modifying cardiovascular risk factors and improving glycemic control in patients with T2DM. Aleglitazar combines the lipid benefits of fibrates and the insulin-sensitizing benefits of thiazolidinediones.

Related Prodcuts:

Talazoparib; Miriplatin; Scriptaid; Ceritinib; CGK733; Tacedinaline; P005091; PR-619; Gemcitabine; Gemcitabine HCL; Terbinafine hydrochloride; Mitomycin C; Clevudine; Givinostat hydrochloride monohydrate

[1]. Bénardeau A, Verry P, Atzpodien EA, et al. Effects of the dual PPAR-α/γ agonist aleglitazar on glycaemic control and organ protection in the Zucker diabetic fatty rat. Diabetes Obes Metab. 2013 Feb;15(2):164-74.

[2]. Younk LM, Uhl L, Davis SN. Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk. Expert Opin Drug Metab Toxicol. 2011 Jun;7(6):753-63.